What we do
What we know
Who we are
For around 10 years, leukemia patients have been treated with CAR T-cell therapy as a last resort. Patients are given genetically modified T cells that specifically recognize and eliminate the diseased cells with their antigen-specific receptors.
Would you like to know how you can use market intelligence for your company? Would you like to learn more about us? Just send us an email or give us a call. We will contact you immediately.
Vangerowstraße 18/1 69115 Heidelberg Phone: +49 6221 – 914 00 0
By sending this form you agree that SVP Deutschland AG may electronically collect, store, and process your contact data. Please refer to our privacy policy for further information.
